Cipla Limited, a global healthcare company headquartered in Mumbai, India, today announced its intention to make investments of up to £100 million ($171 million) in its UK subsidiary over the next few years

The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines as well as research and development, clinical trials, and further expansion internationally and in the UK.

Source: Cipla